Physician profile
Alberto Larrieu
NPI 1447209614
$2,903.17
in general payments reported to CMS, 2019-2025
17 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $72.42 · 2021: $67.86 · 2022: $336 · 2023: $486 · 2024: $1,319 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,214.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $897.09 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $396.04 | 2022-2024 | Caplyta |
| Braeburn INC. | $244.23 | 2023-2025 | Brixadi |
| Alkermes, INC. | $170.46 | 2019-2023 | Vivitrol |
| Revance Therapeutics, INC. | $155.54 | 2024-2025 | Daxxify |
| Takeda Pharmaceuticals U.S.A., INC. | $149.23 | 2021-2024 | Trintellix |
| Novo Nordisk INC | $133.82 | 2023-2024 | Wegovy |
| Neurocrine Biosciences, INC. | $127.88 | 2025 | |
| Allergan, INC. | $125.33 | 2019-2022 | |
| Daiichi Sankyo INC. | $113.40 | 2022 | |
| Abbvie INC. | $95.44 | 2023-2025 | |
| Galderma Laboratories, L.P. | $95.24 | 2022-2025 | Dysport |
| Merz North America, INC. | $79.50 | 2019-2021 | |
| Bausch Health US, LLC | $66.59 | 2023-2024 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $27.79 | 2023-2024 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $12.95 | 2021 | |
| Orexo US, INC. | $12.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Larrieu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.